These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 3121275)

  • 21. Comparative study of encainide and disopyramide in chronic ventricular arrhythmias: a double-blind placebo-controlled crossover study.
    Caron JF; Libersa CC; Kher AR; Kacet S; Wanszelbaum H; Dupuis BA; Poirier JM; Lekieffre JP
    J Am Coll Cardiol; 1985 Jun; 5(6):1457-63. PubMed ID: 2582017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New drugs for treating cardiac arrhythmias.
    Benchimol A; Desser KB
    Postgrad Med; 1981 Jan; 69(1):77-84. PubMed ID: 6780988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anti-arrhythmia effect of long-term encainide in chronic ventricular extrasystole].
    Dumoulin P; Jaillon P; Kher A; Poirier JM; Cheymol G; Valty J; Flammang D; Coumel P; Medvedowsky JL; Barnay C
    Arch Mal Coeur Vaiss; 1985 Oct; 78 Spec No():105-9. PubMed ID: 2420299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of supraventricular arrhythmias with encainide.
    Pool PE
    Am J Cardiol; 1986 Aug; 58(5):55C-57C. PubMed ID: 3092621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of frequent ventricular arrhythmia with encainide: assessment using serial ambulatory electrocardiograms, intracardiac electrophysiologic studies, treadmill exercise tests, and radionuclide cineangiographic studies.
    DiBianco R; Fletcher RD; Cohen AI; Gottdiener JS; Singh SN; Katz RJ; Bates HR; Sauerbrunn B
    Circulation; 1982 Jun; 65(6):1134-47. PubMed ID: 6804110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of incessant supraventricular tachycardia by intravenous and oral encainide.
    Brugada P; Abdollah H; Wellens HJ
    J Am Coll Cardiol; 1984 Dec; 4(6):1255-60. PubMed ID: 6438205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cardiac arrhythmia suppression trial: implications for antiarrhythmic drug development.
    Pratt CM; Moye L
    J Clin Pharmacol; 1990 Nov; 30(11):967-74. PubMed ID: 2122983
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of the efficacy of newly developed antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias.
    Hellestrand KJ
    Eur Heart J; 1984 Sep; 5 Suppl B():87-94. PubMed ID: 6437822
    [No Abstract]   [Full Text] [Related]  

  • 29. Antiarrhythmic agents for chronic ventricular arrhythmias.
    Nestico PF; Morganroth J
    Compr Ther; 1987 Apr; 13(4):26-35. PubMed ID: 3105950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics.
    Roden DM; Reele SB; Higgins SB; Mayol RF; Gammans RE; Oates JA; Woosley RL
    N Engl J Med; 1980 Apr; 302(16):877-82. PubMed ID: 6767186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias.
    Morganroth J; Somberg JC; Pool PE; Hsu PH; Lee IK; Durkee J; Salerno DM
    J Am Coll Cardiol; 1986 Jan; 7(1):9-16. PubMed ID: 3079781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy of oral encainide in frequent and repetitive ventricular arrhythmias.
    Bongiorni MG; Levorato D; Arlotta C; Paperini L; Contini C
    Eur Heart J; 1988 Jul; 9(7):765-76. PubMed ID: 3139413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New drugs for treatment of ventricular arrhythmias.
    Heger JJ; Prystowsky EN; Zipes DP
    Heart Lung; 1981; 10(3):475-83. PubMed ID: 6785255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Moricizine. A review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias.
    Fitton A; Buckley MT
    Drugs; 1990 Jul; 40(1):138-67. PubMed ID: 2202581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electrophysiologic and electrocardiographic effects, efficacy and safety of encainide in malignant ventricular arrhythmias associated with coronary artery disease.
    Weintraub AR; Manolis AS; Estes NA
    Am J Cardiol; 1990 Oct; 66(12):947-53. PubMed ID: 2121017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemodynamic effects of encainide in patients with ventricular arrhythmia and poor ventricular function.
    Sami MH; Derbekyan VA; Lisbona R
    Am J Cardiol; 1983 Sep; 52(5):507-11. PubMed ID: 6412535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative antiarrhythmic actions of encainide and its major metabolites.
    Gomoll AW; Byrne JE; Mayol RF
    Arch Int Pharmacodyn Ther; 1986 Jun; 281(2):277-97. PubMed ID: 3092755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
    Bigger JT
    Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased incidence of side effects after encainide: a newly developed antiarrhythmic drug.
    Berchtold-Kanz E; Schwarz G; Hust M; Nitsche K; Just H
    Clin Cardiol; 1984 Sep; 7(9):493-7. PubMed ID: 6442223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of drug effects on spontaneous and induced ventricular arrhythmias in a 24-h canine infarction model.
    Gomoll AW
    Arzneimittelforschung; 1987 Jul; 37(7):787-94. PubMed ID: 3118889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.